Collegium Pharmaceutical (COLL) Total Liabilities (2014 - 2026)

Collegium Pharmaceutical has reported Total Liabilities for 13 years, with the latest figure at $1.8 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 34.07% year-over-year to $1.8 billion in Q2 2026; TTM through Jun 2026 was $1.8 billion, a 34.07% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 5.55% from the prior year.
• Total Liabilities was $1.8 billion for Q2 2026 at Collegium Pharmaceutical, up from $1.3 billion in the prior quarter.
• The five-year high for Total Liabilities was $1.8 billion in Q2 2026, with the low at $836.8 million in Q2 2024.
• Average Total Liabilities over 5 years is $1.2 billion, with a median of $1.0 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 127.49% in 2022, then decreased 17.4% in 2024.
• Over 5 years, Total Liabilities stood at $979.3 million in 2022, then fell by 3.21% to $947.9 million in 2023, then jumped by 51.36% to $1.4 billion in 2024, then dropped by 5.55% to $1.4 billion in 2025, then surged by 34.59% to $1.8 billion in 2026.
• The last three Total Liabilities figures came in at $1.8 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.